Global Spina Bifida Treatment Market By Diagonsis (Blood Tests, Ultrasound, Amniocentesis), By End-User (Hospitals, Clinics, Diagnostic Centers, Other End-User), By Region and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2019–2029

Spina bifida is a congenital fault in which the membrane around the spine and spinal cord not entirely closed during early pregnancy development. There are three main types: occult spina bifida, meningocele, and spinal meningocele. The most common location is the lower back, but in rare cases, it may be the middle back or neck. Occultism has no or only mild signs and may include hairy plaques, dimples, dark spots, or swelling of the back in the spinal space. Meningoceles usually cause a sac in the spinal area and cause mild problems. Myelomeningocelecele also called as open spina bifida, is the most severe form. Related issues include poor walking ability, bowel or bladder control problems, hydrocephalus (hydrocephalus), spinal cord tethering, and latex allergies. Learning problems are relatively rare. Spina bifida thought to be a combination of genetic and environmental factors. After giving birth to a child, or if one of the parents has the disease, the next child also has a 4% chance of being affected. Insufficient folate in the diet before and after pregnancy also plays an important role. Other risk factors include certain antiepileptic drugs, obesity, and poor control of diabetes.

A maternal blood test can screen Spina bifida but is usually diagnose by ultrasound. (MSAFP) Maternal serum alpha-fetoprotein test-For the MSAFP test, a mother’s blood sample is taken and tested for (AFP) alpha-fetoprotein, a protein produced by infants. A small amount of AFP passes through the placenta and into the mother’s blood is normal. But abnormally high levels of alpha-fetoprotein suggest that infants have neural tube defects, like spina bifida, although high levels of AFP do not always occur in spina bifida. Test to confirm high AFP levels- Change in AFP can be caused by other reasons — like a miscalculation in fetal stage or multiple babies — so the doctor may ask for a blood test for verification. If the outcomes are still high, a patient needs to test further, including an ultrasound test. Ultrasound-Fetal Ultrasound is the correct way to diagnose spina bifida before delivery. An ultrasound test can be performed during the (11 to 14 weeks) first trimester and during the (18 to 22 weeks) second trimester. Spina bifida can accurately be diagnosed during the (18 to 22 weeks) ultrasound scan. Therefore, this test is essential to recognize and rule out congenital abnormalities. Advanced version if an ultrasound test can also detect marks of spina bifida, like the open spine or specific features in a baby’s brain, which indicates spina bifida. In the hands of experts, ultrasound can also effectively assess severity.

Manufacturers are developing and using various distribution chains to gain a more significant market share. Close ties with retailers to increase sales and impact on customers also used as a strategy to enhance demand. It also outsources manufacturing to low-cost offshore areas like China. Due to compulsory screening, the incidence of spina bifida in the region has increased, and technological advancements, especially developments in stents, have dominated the market for spina bifida. According to the Centers for Disease Control and Prevention (CDC), nearly 1,500 babies in the United States suffer from spina bifida each year. Europe is the second-largest market for spina bifida, which is expected to grow due to factors such as the current revision of reimbursement policies. The Asia Pacific is expected to drive the fastest growth due to a large number of patients and the expansion of healthcare. An increase in healthcare spending and economic development have provided momentum for the Asia-Pacific market. Due to weak economic growth, lack of medical facilities, and low income, the Middle East and Africa currently have the lowest share of the global Spina Bifida market. However, due to higher public health spending, the Gulf states of Saudi Arabia and the UAE are expected to drive significant market growth.

Segmentation:

Based on Type:

• Occulta
• Closed Neural Tube Defects
• Meningocele
• Myelomeningocele

Based on Diagnosis:

• Blood Tests
• Ultrasound
• Amniocentesis

Based on Treatment:

• Medical Procedure
• Surgery
• Oral Medications

Based on End-User:

• Hospitals
• Clinics
• Diagnostic Centers
• Other End-User

Based on Country:

• North America
• Latin America
• South Asia
• East Asia
• MEA

Key Players:

• Boston Scientific
• B. Fleet
• R. Bard Inc.
• Braun Melsungen AG
• ConvaTec Group plc
• Hollister Incorporated
• Cook Medical
• Covidien Private Ltd
• Ethicon
• Wellspect Healthcare
• Fujifilm